Giard R W M
Medisch Centrum Rijnmond-Zuid, locatie Clara, afd. Klinische Pathologie, Postbus 9119, 3007 AC Rotterdam.
Ned Tijdschr Geneeskd. 2008 Mar 15;152(11):599-602.
The presence or absence of lymph node metastases is pivotal for the estimation of prognosis in carcinoma patients. The presence of lymph node metastases in patients with colorectal carcinoma (CRC) is an indicator of poor prognosis and adjuvant treatment is increasingly being given to these patients. For the patient much depends on effective staging of CRC. In patients with TNM stage II CRC, prognosis is related to the actual number of nodes harvested: those in whom fewer nodes are harvested fare less well. Understaging was suspected and therefore protocols now require a minimum number of nodes. Recent observational studies, however, have questioned understaging as a plausible mechanism. Tumour, biological or patient-related factors seem to be more likely. The number of nodes is not a suitable measure for the quality of pathological staging of CRC. Instead of this outcome measure, more attention should be paid to processes and future standards must be based on sound experimental evidence and not on observational surveys.
淋巴结转移的有无对于评估癌症患者的预后至关重要。结直肠癌(CRC)患者出现淋巴结转移是预后不良的指标,这些患者越来越多地接受辅助治疗。对于患者来说,很大程度上取决于CRC的有效分期。在TNM II期CRC患者中,预后与所采集淋巴结的实际数量有关:采集淋巴结较少的患者预后较差。有人怀疑分期不足,因此现在的方案要求有最少数量的淋巴结。然而,最近的观察性研究对分期不足作为一种合理机制提出了质疑。肿瘤、生物学或患者相关因素似乎更有可能。淋巴结数量不是CRC病理分期质量的合适衡量标准。不应将此结果指标作为重点,而应更多地关注过程,未来的标准必须基于可靠的实验证据,而不是观察性调查。